



(86) Date de dépôt PCT/PCT Filing Date: 1998/06/08
(87) Date publication PCT/PCT Publication Date: 1998/12/17
(45) Date de délivrance/Issue Date: 2007/10/16
(85) Entrée phase nationale/National Entry: 1998/08/13
(86) N° demande PCT/PCT Application No.: EP 1998/003427
(87) N° publication PCT/PCT Publication No.: 1998/056772
(30) Priorité/Priority: 1997/06/10 (CH1404/97)


(51) Cl.Int./Int.Cl. *C07D 249/04* (2006.01),
A61K 31/41 (2006.01)

(72) Inventeurs/Inventors:
PORTMANN, ROBERT, CH;
HOFMEIER, URS CHRISTOPH, CH;
BURKHARD, ANDREAS, CH;
SCHERRER, WALTER, CH;
SZELAGIEWICZ, MARTIN, CH

(73) Propriétaire/Owner:
NOVARTIS AG, CH

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : MODIFICATION CRISTALLINE DE 1-(2,6-DIFLUOROBENZYLE)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE ET SON UTILISATION EN TANT QU'ANTI-EPILEPTIQUE
(54) Title: CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC



(I)

(57) Abrégé/Abstract:

The invention relates to the novel modification A or A' of the compound 1-(2, 6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of formula (I), its use for the treatment of epilepsy, and pharmaceutical preparations comprising this crystal modification.

